Cytodyn Inc (CYDY)

[stockorus]

I looked at the 4/11 news and it says:

Veru said patients hospitalized with moderate to severe COVID-19, who were at high risk for adult respiratory distress syndrome (ARDS) and death, its oral sabizabulin led to a "clinically and statistically meaningful" 55% reduction in deaths. The Independent Data Safety Monitoring Committee "unanimously" recommended the Phase 3 trial be halted early because of efficacy, with no safety concerns identified.

That's pretty much the type of news we wanted to see in cd12, and what some of us think could very well have happened had we the right trial protocol and patients. It seems VERU got almost a green signal now; unless our Brazil trials are going anywhere, I don't see how we are going to catch up in this space, as far as this waning pandemic is concerned. (However, I don't know if their severe group includes ecmo patients (critical).)

In any case, getting our trials completed is important because if LL does work in these Covid indications as well as we hope, then it could reveal much more about its potential in general than just for one disease. Its more than just about Covid and the short-term money it can generate (as much as we need it). And as you said, Leronlimab could still prove itself the better drug even here.